跳至主要内容
临床试验/NCT00667979
NCT00667979已完成4 期

A Pilot, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Vardenafil Versus Placebo Administered 12, 18 and 24 Hours Prior to Initiation of Sexual Intercourse in Subjects With ED

Bayer0 个研究点目标入组 264 人开始时间: 2004年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Bayer
入组人数
264
主要终点
Sexual encounter profile Question 3

研究概览

简要总结

Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. However, there remains no prospectively obtained data on the maximal time of effectiveness of vardenafil. The goal of the current study was to determine if vardenafil will significantly increase the percentage of successful intercourse attempts from 12 to 24 hours following dosing. A total of three time points 12, 18, and 24 hours were assessed in this pilot study to better quantify the effect of vardenafil.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Men >/= 18 years of age
  • ED >/= 6 months
  • Stable sexual relationship for > 6 months

排除标准

  • Primary hypoactive sexual desire
  • History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month
  • Nitrate therapy
  • Other exclusion criteria apply according to the Summary of Product Characteristics

研究组 & 干预措施

Arm 1

Experimental

干预措施: Levitra (Vardenafil, BAY38-9456) (Drug)

Arm 2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Sexual encounter profile Question 3

时间窗: 6 weeks

次要结局

  • Safety and Tolerability(6 weeks)

研究者

发起方
Bayer
申办方类型
Industry

相似试验